Pages
Recognition of Staff Excellence (ROSE) award
https://dchs.nhs.uk/news/recognition-staff-excellence-rose-award
Lynne’s Nursing Times judging journey
https://dchs.nhs.uk/my_dchs/show-me/staff-news-my-download/lynnes-nursing-times-judging-journey
Quality Assurance - How Quality Makes a Difference to You in DCHS
https://dchs.nhs.uk/about-us/quality-heart-our-care/quality-assurance/quality-assurance-flipbook
I'd like to do business with DCHS
https://dchs.nhs.uk/join-us/do-business-us/procurement/id-do-business-dchs
We need your help to continue shaping our work on workforce race & disability equality and inclusion
Files
Disclosure Ref 202207 - Website information.pdf
FOI disclosure
PGN15 Evaluating Quotes & Tenders
DCHS tender process
Self-isolation_and_testing_what_you_need_to_know_now__-_SM_poster.pdf
DCHS Declaraton - Public Bolsolver.pdf
Essential foundation poster quality conversations - 20 February.pdf
A2a - DEPRIVATION OF LIBERTY SAFEGUARDS FORM 1 (P35)
Safeguarding Form 1,P35,DoLs
Clinical Harms Review Additional detail for Service Level SOP (S130)
This document should be read in conjunction with the overarching DCHS Standard Operating procedure on Clinical Harms which outlines the processes to be followed to deliver a consistent approach to: • Utilising a proactive method of risk stratification to minimise clinical harm as a result of delays in care. • Embedding systems which consider health inequalities. • Monitoring waiting times against defined thresholds across pathways of care. • Delivering personalised, patient-centred communications to patients who are waiting for care. • Implementing Harm Reviews for the that support the Trusts governance and assurance processes and maintains practice in line with national expectations.
Clinical Harms Review Additional detail for Service Level SOP (S133)
This document should be read in conjunction with the overarching DCHS Standard Operating procedure on Clinical Harms which outlines the processes to be followed to deliver a consistent approach to. • Risk stratification to minimise clinical harm as a result of delays in care. • Embedding systems which take into account health inequalities. • Monitoring waiting times against defined thresholds across pathways of care. • Delivering personalised, patient-centred communications to patients who are waiting for care. • Implementing Harm Reviews that support the Trusts governance and assurance processes and maintains practice in line with national expectations. The intention of the service level document is to provide specific detail on. • The risk stratification process in operation and clinically appropriate to specific service lines and patient cohorts • Waiting time thresholds for the relevant patient pathways
A2 - Stop And Watch